MedTrace Logo

Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma

NCT02445209 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2015-05-15

No results posted yet for this study

Summary

The purpose of the study is to compare efficacy and safety of palliative chemotherapy EOX and mDCF regimens in the first-line treatment of patients with advanced HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma

Conditions

  • HER2 Negative Gastric Cancer

Interventions

OTHER

EOX

combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine

OTHER

mDCF

combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin

Sponsors & Collaborators

  • Jagiellonian University

    lead OTHER

Principal Investigators

  • Sebastian Ochenduszko, M.D., PhD · Jagiellonian University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2014-02-28
Completion
2014-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02445209 on ClinicalTrials.gov